Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
NYSE MKT:LCTX
Holding LCTX?
Track your performance easily
LCTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.77 - $1.61
Previous Close$0.9
Volume9.93M
Average Volume (3M)415.12K
Market Cap
$170.56M
Enterprise Value$139.20M
Total Cash (Recent Filing)$32.71M
Total Debt (Recent Filing)$2.75M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Mar 06, 2025EPS Estimate
-$0.04Last Dividend Ex-Date
Nov 29, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding188,837,375
10 Day Avg. Volume1,427,967
30 Day Avg. Volume415,117
Standard Deviation0.15
R-Squared0.19
Alpha-0.00302
Financial Highlights & Ratios
Price to Book (P/B)1.83
Price to Sales (P/S)19.56
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.99
Enterprise Value/Gross Profit16.82
Enterprise Value/Ebitda-6.61
Forecast
1Y Price Target
$4.00Price Target Upside523.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Lineage Therap News
PremiumCompany Announcements
Lineage Therap Announces $66 Million Direct Offering
PremiumCompany Announcements
Lineage Cell Therapeutics Reports Q3 2024 Highlights
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.77 and its highest was $1.61 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 105 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Nov 14, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.02.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. pays a Notavailable dividend of $0.11 which represents an annual dividend yield of N/A. See more information on Lineage Cell Therapeutics, Inc. dividends here
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -$0.04.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 188,837,370 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -2.273%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Among the largest hedge funds holding Lineage Cell Therapeutics, Inc.’s share is Defender Capital, LLC.. It holds Lineage Cell Therapeutics, Inc.’s shares valued at 5M.
---
Lineage Therap Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (523.64% Upside)
$4.00 (523.64% Upside)
Hedge Fund Trend
Increased
By 29.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.94%
12-Months-Change
Fundamentals
Return on Equity
-29.95%
Trailing 12-Months
Asset Growth
-9.00%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
---
LCTX Earnings Call
Q3 2024
0:00 / 0:00
---
LCTX Stock 12 Month Forecast
Average Price Target
$4.00
▲(523.64% Upside)
Technical Analysis
Best Analysts Covering LCTX
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+17.13%
initiated a buy rating 4 days ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +17.13% per trade.
---